Towa Pharmaceutical DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Manufacturing and Marketing Approval for Three Ingredients and Eight Items

Details : Company has been granted manufacturing and marketing approval for the generic version for zonisamide capsule for the treatment of Parkinson's disease.

Brand Name : Zonegran-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 15, 2024

Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

02 Towa Pharmaceutical

Japan

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Esomeprazole Magnesium

Therapeutic Area : Gastroenterology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Notice of Approval for Esomeprazole Capsules with New Manufacturing Plant Addition

Details : Esomeprazole magnesium hydrate capsules is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

Brand Name : Esomeprazole-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 14, 2024

Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

03 Towa Pharmaceutical

Japan

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Eldecalcitol

Therapeutic Area : Musculoskeletal

Highest Development Status : Approved

Recipient : Chugai Pharmaceutical

Deal Size : Not Applicable

Deal Type : Not Applicable

Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment

Details : Edirol® Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D3 preparation). Chugai manufactures Edirol Tablet and supplies to Towa.

Brand Name : Edirol

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 09, 2022

Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.

04 Towa Pharmaceutical

Japan

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Eldecalcitol

Therapeutic Area : Musculoskeletal

Highest Development Status : Approved

Recipient : Chugai Pharmaceutical

Deal Size : Not Applicable

Deal Type : Not Applicable

Chugai Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet

Details : Edirol (eldecalcitol), is an active vitamin D3 derivative created based on Chugai’s long-standing vitamin D research. Chugai takes responsibilities as a holder of the approval, Towa will be responsible for marketing and providing information on use of ...

Brand Name : Edirol

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

05 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Cabazitaxel

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Natco Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

Breckenridge Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (Generic for Jevt...

Details : Cabazitaxel Intravenous Powder (generic for Jevtana Kit®), is a Microtubule inhibitor, available in the 60mg/1.5mL (40mg/mL) strength used fo the treatment of Prostate cancer.

Brand Name : Cabazitaxel-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 01, 2022

06 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Cabazitaxel

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Natco Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

Natco Pharma's Partner Breckenridge Gets FDA Nod for Prostate Cancer Drug

Details : Cabazitaxel intravenous powder of strength 60mg/1.5ml (40mg/ml), is an antineoplastic agent and a microtubule inhibitor used in the treatment of prostate cancer.

Brand Name : Cabazitaxel-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 25, 2022

07 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Dabigatran Etexilate Mesylate

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Breckenridge Announces Tentative Approval of its ANDA for Dabigatran Etexilate Capsules (generic f...

Details : Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.

Brand Name : Dabigatran Etexilate-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 22, 2022

08 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Miglustat

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Breckenridge Announces Approval of its ANDA for Miglustat Capsules (generic for Zavesca®)

Details : Miglustat Capsules (generic for Zavesca), 100mg strength, is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for first step in synthesis of most glycosphingolipids.

Brand Name : Miglustat-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 21, 2022

09 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Penicillamine

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Recipient : Aggrega Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cup...

Details : Penicillamine Capsules, USP (generic for Cuprimine®), a chelating agent recommended for the removal of excess copper in patients with Wilson's disease also in cystinuria, and in patients with severe, active rheumatoid arthritis.

Brand Name : Pencillamine-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 20, 2022

10 Breckenridge Pharmaceutical

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

Lead Product(s) : Penicillamine

Therapeutic Area : Genetic Disease

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cup...

Details : Cuprimine-Generic (penicillamine) is a copper chelating agent, small molecule drug candidate, which is being evauated for the treatment of Wilson's disease.

Brand Name : Cuprimine-Generic

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 20, 2022